NCT06531447

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: The National Center of Oncology, Azerbaijan · Other Government
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer

Detailed description

Using combination of gemcitabine plus cisplatine as first line treatment patients with locally advanced breast cancer with high TUBB3 expression

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Cisplatin	Every 21 days 6 cycles
DRUG	Gemcitabine	Every 21 days (First and 8th days) 6 cycles
DRUG	Doxorubicin	Every 21 days 4 cycles
DRUG	Cyclophosphamide	Every 21 days 4 cycles
DRUG	Paclitaxel	Every 21 days 4 cycles or once a week for 12 weeks

Timeline

• Start date: 2014-05-01
• Primary completion: 2017-11-01
• Completion: 2027-05-01
• First posted: 2024-08-01
• Last updated: 2024-08-01

Locations

1 site across 1 country: Azerbaijan